FEEDBACK
CONTACT US
The
Westaim Corporation
invests, directly and indirectly, through acquisitions, joint ventures and other arrangements, with the objective of providing its shareholders with capital appreciation and real wealth preservation.
Westaim
holds a 75 per cent interest in
NUCRYST Pharmaceuticals Corp.
(NASDAQ: NCST; TSX: NCS).
Westaim's
common shares are listed on
The Toronto Stock Exchange
under the trading symbol WED.
WED.T
:
0.33
+0.03
History
Management
Corporate Governance
Board of Directors
NUCRYST Pharmaceuticals Corp.
Nanocrystalline
Technology
NUCRYST's Licensing Agreement
Company Reports
Regulatory Filings
Conference Calls & Webcasts
Stock Quote
Press Releases
TODAYS STOCK QUOTE
Our Investments
NUCRYST
Pharmaceuticals Corp.
Develops, manufactures and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology.
Quick Links
Annual Meeting of Shareholders Webcast - May 12, 2009
2008 Fourth Quarter Results Webcast - February 19, 2009
Annual Reports
Quarterly Reports
News RSS
Latest
View All
Westaim News
May 11, 2009
Westaim announces 2009 first quarter results
May 7, 2009
Webcast Advisory - The Westaim Corporation Webcast of Annual Meeting of Shareholders
April 3, 2009
Westaim enters into Management Services Agreement
© 2006 The Westaim Corporation
Legal
Website Recording by Q4 Web Systems
3.5.301.1065